Autologous hematopoietic stem cell transplantation in neuromyelitis optica: A registry study of the EBMT Autoimmune Diseases Working Party

Multiple Sclerosis Journal

Volumn 21, Issue 2, 2015, Pages 189-197

  Greco, Raffaella ^a   Bondanza, Attilio ^a   Oliveira, Maria Carolina ^b   Badoglio, Manuela ^c   Burman, Joachim ^d   Piehl, Fredrik ^e   Hagglund, Hans ^e,f   Krasulova, Eva ^g   Simões, Belinda Pinto ^b   Carlson, Kristina ^h   Pohlreich, David ^g   Labopin, Myriam ^c   Saccardi, Riccardo ⁱ   Comi, Giancarlo ^a   Mancardi, Gian Luigi ^j   Bacigalupo, Andrea ^k   Ciceri, Fabio ^a   Farge, Dominique ^l  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c HÔPITAL SAINT ANTOINE   (France)

^d UPPSALA UNIVERSITY   (Sweden)

^e KAROLINSKA INSTITUTE   (Sweden)

^f KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^g CHARLES UNIVERSITY   (Czech Republic)

^h University Hospital   (Sweden)

ⁱ CAREGGI UNIVERSITY HOSPITAL   (Italy)

^j UNIVERSITY OF GENOA   (Italy)

^k UNIVERSITY OF GENOA   (Italy)

^l SAINT LOUIS HOSPITAL   (France)

more..

Author keywords

Autologous stem cell transplantation; Disease outcome; Neuromyelitis optica

Indexed keywords

AQUAPORIN 4 ANTIBODY; AZATHIOPRINE; CYCLOPHOSPHAMIDE; GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN G; METHOTREXATE; MITOXANTRONE; RITUXIMAB; STEROID; THIOTEPA; THYMOCYTE ANTIBODY;

ADOLESCENT; ADULT; ARTICLE; AUTOIMMUNE THYROIDITIS; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CHILD; CLINICAL ARTICLE; DISEASE COURSE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; EXPANDED DISABILITY STATUS SCALE; FEBRILE NEUTROPENIA; FEMALE; FRACTURE; HEALTH SURVEY; HERPES ZOSTER; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; LUNG ASPERGILLOSIS; MAINTENANCE THERAPY; MALE; MULTICENTER STUDY; MYELOOPTIC NEUROPATHY; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PERIPHERAL BLOOD STEM CELL; PROGRESSION FREE SURVIVAL; RECURRENCE FREE SURVIVAL; REFRACTORY NEUROMYELITIS OPTICA; REGISTER; RELAPSE; RETROSPECTIVE STUDY; TREATMENT FAILURE; TUMOR ENGRAFTMENT; ADVERSE EFFECTS; AUTOTRANSPLANTATION; CLINICAL TRIAL; FOLLOW UP; HEMATOPOIETIC STEM CELL TRANSPLANTATION; MIDDLE AGED; NEUROMYELITIS OPTICA; PROCEDURES; YOUNG ADULT;

ADULT; FEMALE; FOLLOW-UP STUDIES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; NEUROMYELITIS OPTICA; OUTCOME ASSESSMENT (HEALTH CARE); REGISTRIES; TRANSPLANTATION, AUTOLOGOUS; YOUNG ADULT;

EID: 84923078724     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458514541978     Document Type: Article

References (35)

1. Sellner J, Boggild M, Clanet M, et al. EFNS guidelines on diagnosis and management of neuromyelitis optica. Eur J Neurol. 2010 ; 17: 1019-1032
2. Mandler RN. Neuromyelitis optica - Devic's syndrome, update. Autoimmun Rev. 2006 ; 5: 537-543
3. Matiello M, Lennon VA, Jacob A, et al. NMO-IgG predicts the outcome of recurrent optic neuritis. Neurology. 2008 ; 70: 2197-2200
4. Weinshenker BG, Wingerchuk DM, Vukusic S, et al. Neuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitis. Ann Neurol. 2006 ; 59: 566-569
5. Lennon VA, Wingerchuk DM, Kryzer TJ, et al. A serum autoantibody marker of neuromyelitis optica: Distinction from multiple sclerosis. Lancet. 2004 ; 364: 2106-2112
6. Kim SM, Waters P, Woodhall M, et al. Utility of aquaporin-4 antibody assay in patients with neuromyelitis optica spectrum disorders. Mult Scler. 2013 ; 19: 1060-1067
7. Ratelade J, Verkman AS. Neuromyelitis optica: Aquaporin-4 based pathogenesis mechanisms and new therapies. Int J Biochem Cell Biol. 2012 ; 44: 1519-1530
8. Wingerchuk DM, Lennon VA, Pittock SJ, et al. Revised diagnostic criteria for neuromyelitis optica. Neurology. 2006 ; 66: 1485-1489
9. Matiello M, Jacob A, Wingerchuk DM, et al. Neuromyelitis optica. Curr Opin Neurol. 2007 ; 20: 255-260
10. Wingerchuk DM, Hogancamp WF, O'Brien PC, et al. The clinical course of neuromyelitis optica (Devic's syndrome). Neurology. 1999 ; 53: 1107-1114
11. Keegan M, Pineda AA, McClelland RL, et al. Plasma exchange for severe attacks of CNS demyelination: Predictors of response. Neurology. 2002 ; 58: 143-146
12. Collongues N, de Seze J. Current and future treatment approaches for neuromyelitis optica. Ther Adv Neurol Disord. 2011 ; 4: 111-121
13. Killian JM, Bressler RB, Armstrong RM, et al. Controlled pilot trial of monthly intravenous cyclophosphamide in multiple sclerosis. Arch Neurol. 1988 ; 45: 27-30
14. Weinstock-Guttman B, Ramanathan M, Lincoff N, et al. Study of mitoxantrone for the treatment of recurrent neuromyelitis optica (Devic disease). Arch Neurol. 2006 ; 63: 957-963
15. Jacob A, Matiello M, Weinshenker BG, et al. Treatment of neuromyelitis optica with mycophenolate mofetil: Retrospective analysis of 24 patients. Arch Neurol. 2009 ; 66: 1128-1133
16. Kitley J, Elsone L, George J, et al. Methotrexate is an alternative to azathioprine in neuromyelitis optica spectrum disorders with aquaporin-4 antibodies. J Neurol Neurosurg Psychiatry. 2013 ; 84: 918-921
17. Jacob A, Weinshenker BG, Violich I, et al. Treatment of neuromyelitis optica with rituximab: Retrospective analysis of 25 patients. Arch Neurol. 2008 ; 65: 1443-1448
18. Kim SH, Huh SY, Lee SJ, et al. A 5-year follow-up of rituximab treatment in patients with neuromyelitis optica spectrum disorder. JAMA Neurol. 2013 ; 70: 1110-1117
19. Pittock SJ, Lennon VA, McKeon A, et al. Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: An open-label pilot study. Lancet Neurol. 2013 ; 12: 554-562
20. Lu Z, Ye D, Qian L, et al. Human umbilical cord mesenchymal stem cell therapy on neuromyelitis optica. Curr Neurovasc Res. 2012 ; 9: 250-255
21. Muraro PA, Douek DC. Renewing the T cell repertoire to arrest autoimmune aggression. Trends Immunol. 2006 ; 27: 61-67
22. Saccardi R, Kozak T, Bocelli-Tyndall C, et al. Autologous stem cell transplantation for progressive multiple sclerosis: Update of the European Group for Blood and Marrow Transplantation autoimmune diseases working party database. Mult Scler. 2006 ; 12: 814-823
23. Saccardi R, Freedman MS, Sormani MP, et al. A prospective, randomized, controlled trial of autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: A position paper. Mult Scler. 2012 ; 18: 825-834
24. Burt RK, Loh Y, Cohen B, et al. Autologous non-myeloablative haemopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: A phase I/II study. Lancet Neurol. 2009 ; 8: 244-253
25. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: An Expanded Disability Status Scale (EDSS). Neurology. 1983 ; 33: 1444-1452
26. Snowden JA, Saccardi R, Allez M, et al. Haematopoietic SCT in severe autoimmune diseases: Updated guidelines of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant. 2012 ; 47: 770-790
27. Matiello M, Pittock SJ, Porrata L, et al. Failure of autologous hematopoietic stem cell transplantation to prevent relapse of neuromyelitis optica. Arch Neurol. 2011 ; 68: 953-955
28. Peng F, Qiu W, Li J, et al. A preliminary result of treatment of neuromyelitis optica with autologous peripheral hematopoietic stem cell transplantation. Neurologist. 2010 ; 16: 375-378
29. Xu J, Ji BX, Su L, et al. Clinical outcome of autologous peripheral blood stem cell transplantation in opticospinal and conventional forms of secondary progressive multiple sclerosis in a Chinese population. Ann Hematol. 2011 ; 90: 343-348
30. van Gelder M, Kinwel-Bohre EP, van Bekkum DW. Treatment of experimental allergic encephalomyelitis in rats with total body irradiation and syngeneic BMT. Bone Marrow Transplant. 1993 ; 11: 233-241
31. Karussis DM, Slavin S, Lehmann D, et al. Prevention of experimental autoimmune encephalomyelitis and induction of tolerance with acute immunosuppression followed by syngeneic bone marrow transplantation. J Immunol. 1992 ; 148: 1693-1698
32. Karussis D, Vourka-Karussis U, Mizrachi-Koll R, et al. Acute/relapsing experimental autoimmune encephalomyelitis: Induction of long lasting, antigen-specific tolerance by syngeneic bone marrow transplantation. Mult Scler. 1999 ; 5: 17-21
33. Greco R, Bondanza A, Vago L, et al. Allogeneic hematopoietic stem cell transplantation for neuromyelitis optica. Ann Neurol. 2014 ; 75: 447-453
34. Van Wijmeersch B, Sprangers B, Rutgeerts O, et al. Allogeneic bone marrow transplantation in models of experimental autoimmune encephalomyelitis: Evidence for a graft-versus-autoimmunity effect. Biol Blood Marrow Transplant. 2007 ; 13: 627-637
35. Hinterberger W, Hinterberger-Fischer M, Marmont A. Clinically demonstrable anti-autoimmunity mediated by allogeneic immune cells favorably affects outcome after stem cell transplantation in human autoimmune diseases. Bone Marrow Transplant. 2002 ; 30: 753-759